September 21, 2018 — At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers will showcase new products that span the continuum of care in cardiology. Introducing solutions in both the laboratory and imaging spaces, Siemens Healthineers will debut a new ultrasound real-time intra-cardiac echo (ICE) catheter and High-Sensitivity Troponin I assays. The company is also a sponsor of the Interventional Imaging and Endovascular Pavilions at TCT, supplying hands-on workshops and simulations for continuing education.
With its new Acuson AcuNav Volume catheter, Siemens Healthineers is the first to market a real-time volume ICE catheter designed to meet the needs of structural heart interventionalists in the tradition of the acuson AcuNav family of catheters. By increasing to 90 x 50 degrees field of view, the new real-time volume ICE catheter provides complete visualization of heart valves, important for successful valve repair or replacement procedures. Along with the established capabilities and benefits of intracardiac echocardiography, such as reducing dose by requiring less fluoroscopy, real-time volume ICE offers clinicians a more flexible approach to sedation. Clinicians can use conscious sedation with the Acuson AcuNav Volume ICE catheter as opposed to general anesthesia, supporting safer and more efficient procedures, improved patient recovery and increased patient throughput. The Acuson AcuNav Volume ICE catheter is available exclusively on the Acuson SC2000 Prime ultrasound system, a complete structural heart disease solution delivering advanced visualization and artificial intelligence (AI)-powered quantification in 2-D and 3-D transthoracic echo ( TTE), transesophageal echo (TEE) and ICE.
Siemens Healthineers will also sponsor training for over 500 physicians at the TCT Interventional Imaging and Endovascular Pavilions. These interactive training workshops at the conference enable participants to experience practical, interactive education and training to be applied to their structural heart, complex percutaneous coronary intervention (PCI) and endovascular procedures. Workshop schedules can be found on the TCT website.
The company has also recently launched two assays that offer high precision to help clinicians diagnose a life-threatening myocardial infarction. High-Sensitivity Troponin I assays (TnIH) for the Atellica IM and Advia Centaur XP/XPT in vitro diagnostic analyzers test troponin levels, which indicate damage to the heart muscle. The new assays offer greater precision to measure slight yet critical changes so physicians can properly triage patients presenting with symptoms. As High-Sensitivity Troponin I assays are designed to detect an early release of cTnl, physicians may be able to diagnose myocardial infarction earlier in the course of care. These TnIH assays meet the latest industry guidelines.
For more information: www.usa.healthcare.siemens.com